Skip to content
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — Januar 2023

Genmab — Januar 2023

Planlagt Fastgjort Låst Flyttet Genmab
644 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • S Offline
    S Offline
    Sukkeralf
    wrote on sidst redigeret af
    #58

    https://endpts.com/amgen-kicks-off-2023-dealmaking-with-busy-adc-upstart-synaffix/

    1 Reply Last reply
    0
    • S Offline
      S Offline
      Sukkeralf
      wrote on sidst redigeret af
      #59

      Er det mon noget i samme stil Genmab/Curevac roder med, som CyTomX/Moderna starter op nu:

      1 Reply Last reply
      0
      • S Offline
        S Offline
        Sukkeralf
        wrote on sidst redigeret af
        #60

        Just a moment...

        favicon

        (firstwordpharma.com)

        1 Reply Last reply
        0
        • P Offline
          P Offline
          ProinvestorNEWS
          wrote on sidst redigeret af
          #61

          FDA Grants Priority Review To Genentech's Glofitamab To Treat R/R Large B-cell Lymphoma https://www.proinvestor.com/investornyt/923812/fda-grants-priority-review-to-genentechs-glofitamab-to-treat-r-r-large-b-cell-lymphoma

          1 Reply Last reply
          0
          • S Offline
            S Offline
            Sukkeralf
            wrote on sidst redigeret af
            #62

            Uha - så er Genmab/Abbvie kun ca halvanden måned i front !!

            1 Reply Last reply
            0
            • S Offline
              S Offline
              Sukkeralf
              wrote on sidst redigeret af
              #63

              Dog stadig sc dosering at skille sig ud på tillige

              1 Reply Last reply
              0
              • BulderB Offline
                BulderB Offline
                Bulder
                wrote on sidst redigeret af
                #64

                "Kun"?? De var flere år bagud i begyndelsen. Roche er indhentet. Kæmpe præstation.

                1 Reply Last reply
                0
                • G Offline
                  G Offline
                  GeorgeBest
                  wrote on sidst redigeret af
                  #65

                  og SC fordelen vel meget stor. Hvis man ser på udviklingen i Darzalex salget siden SC kom på markedet, så udgør SC over 80% så vidt jeg husker

                  1 Reply Last reply
                  0
                  • S Offline
                    S Offline
                    Sukkeralf
                    wrote on sidst redigeret af
                    #66

                    Enig Bulder - det kun kunne godt misforståes i retning af at Abbvie /Genmab ikke gør det godt. Men jo mere tid de er foran des bedre - det er trods alt den markedsdominerende man er oppe imod, så selv måneder tæller her, tænker jeg ! Men enig det er vildt godt gået, at de har indhentet så meget tid 🙂

                    1 Reply Last reply
                    0
                    • E Offline
                      E Offline
                      E_L
                      wrote on sidst redigeret af
                      #67

                      Roche/Genentech is a fierce competitor, I think things would have looked very different without partner AbbVie with it's huge experience and selling power. Just look at how they deal with Humira. No way Genmab would have been able to get through development this fast without them..
                      .

                      1 Reply Last reply
                      0
                      • E Offline
                        E Offline
                        E_L
                        wrote on sidst redigeret af
                        #68

                        The biggest-selling drugs of 2023 https://www.evaluate.com/vantage/articles/analysis/biggest-selling-drugs-2023

                        1 Reply Last reply
                        0
                        • E Offline
                          E Offline
                          E_L
                          wrote on sidst redigeret af
                          #69

                          am I correct that we only saw Jan, apr and may for Dara Symphony Health
                          data?

                          1 Reply Last reply
                          0
                          • E Offline
                            E Offline
                            E_L
                            wrote on sidst redigeret af
                            #70

                            Fate Therapeutics Announces Termination of Collaboration Agreement with Janssen [ CAR NK and CAR T-cell ] https://finance.yahoo.com/news/fate-therapeutics-announces-termination-collaboration-220000222.html another -47% pre market... trading below $6, this was almost $120 a year ago...

                            1 Reply Last reply
                            0
                            • P Offline
                              P Offline
                              ProinvestorNEWS
                              wrote on sidst redigeret af
                              #71

                              Mandagens aviser med Novozymes, TDC og Novo Holdings https://www.proinvestor.com/investornyt/924542/mandagens-aviser-med-novozymes-tdc-og-novo-holdings

                              1 Reply Last reply
                              0
                              • P Offline
                                P Offline
                                ProinvestorNEWS
                                wrote on sidst redigeret af
                                #72

                                Asien: Flotte plusser op til regnskabssæsonen - Tokyo lukket - NY https://www.proinvestor.com/investornyt/924550/asien-flotte-plusser-op-til-regnskabssaesonen-tokyo-lukket-ny

                                1 Reply Last reply
                                0
                                • Helge_LarsenPI-redaktørH Offline
                                  Helge_LarsenPI-redaktørH Offline
                                  Helge_LarsenPI-redaktør
                                  wrote on sidst redigeret af
                                  #73

                                  Godmorgen 🙂

                                  1 Reply Last reply
                                  0
                                  • B Offline
                                    B Offline
                                    bibob
                                    wrote on sidst redigeret af
                                    #74

                                    God morgen. 🙂

                                    1 Reply Last reply
                                    0
                                    • S Offline
                                      S Offline
                                      Stroka
                                      wrote on sidst redigeret af
                                      #75

                                      God morgen 🙂

                                      1 Reply Last reply
                                      0
                                      • E Offline
                                        E Offline
                                        E_L
                                        wrote on sidst redigeret af
                                        #76

                                        JNJ yesterday very positive on Genmab products again; biggest area of growth is MM portfolio; biggest disconnect wih the market is that these drugs do not cannibalise each other but create the treatment paradigm that is different by combining + sequencing these different medicines

                                        1 Reply Last reply
                                        0
                                        • E Offline
                                          E Offline
                                          E_L
                                          wrote on sidst redigeret af
                                          #77

                                          Mariposa/ Rybrevant ; runs through 2024, but potential interim analysis 2023; large market, very large opportunity for growth

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper